CORT Share Price Performance
US$69.00
34.49 (99.94%)
50.1% undervalued intrinsic discount
US$138.25
Fair Value
Price US$69.00
AnalystConsensusTarget US$138.25
Fair ValueUS$138.25
Share PriceUS$69.00
50.1% undervalued intrinsic discount
CORT Community Narratives
AN
Fair Value US$138.25 50.1% undervalued intrinsic discount
Relacorilant Launch And ROSELLA Trial Will Open New Markets
0users have liked this narrative
0users have commented on this narrative
50users have followed this narrative
CORT Community Fair Values
- US$138.25FV50.1% undervalued intrinsic discount38.47%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative50users have followed this narrative5 days ago author updated this narrative
Recent CORT News & Updates
No updates
Corcept Therapeutics Incorporated Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 1.25
- Gross Margin
- 98.30%
- Net Profit Margin
- 18.44%
- Debt/Equity Ratio
- 0%
Corcept Therapeutics Incorporated Competitors
About CORT
- Founded
- 1998
- Employees
- 500
- CEO
- WebsiteView website
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a loss of 2.4% in the Information Technology sector. As for the longer term, the market has actually risen by 20% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading